EDITORIAL SYNOPSIS The authors suggest that their observations show that the method of giving oral anion-binding resins with the injection of 1311-labelled albumin does not give a precise measure of protein loss from the alimentary tract; nevertheless the method may be useful in the diagnosis of disease.
Since protein-losing or 'exudative' enteropathy has been described (Gordon, 1959; Schwartz and Jarnum, 1959) , all workers have wanted to have a quantitative method for the estimation of gastrointestinal protein loss. A method involving the injection of 131I-labelled albumin and the oral administration of an anion-binding resin has recently been elaborated by Jeejeebhoy and Coghill (1961) . The investigations presented here, however, show that this method does not fulfil the demands for exact measurement of gastrointestinal protein loss.
MATERIAL AND METHODS
Two investigations were employed on two groups of patients. In group 1, 50 to 100 Vkc. '311-labelled human protein (albumin and gamma globulin) was injected intravenously, and the urinary clearance of 1311 was measured before and during the oral administration of resin, which was given as Amberlite from the tenth to the fifteenth day, in doses of about 7 g. every four hours. In group 2, about 10 /ic. Na131L was injected subcutaneously, and the percentage faecal activity of 1311 of the total excreted in the urine and faeces before and during the oral administration of resin was measured. Resin was given for five days after a five-day control period.
The age, sex, and diagnosis of the patients are listed in Tables I and II . Several were suspected of suffering from protein-losing enteropathy. To prevent uptake of 1311 by the thyroid, 13 g. potassium iodide was given twice daily, commencing one or two days before the day of injection, between doses of resin. Protein was labelled according to McFarlane's (1956) method, except in one 'This work was supported by grants from Statens Videnskabsfond and King Christian X Fund. patient (KM , Table I ), to whom radioiodinated human serum albumin from the Radiochemical Centre at Amersham was given.
Plasma activity was followed by taking daily blood samples, and activity was measured in homogenized faeces and 24-hour samples of urine. All radioactivity was measured in a well-type scintillation counter, connected with a Tracerlab Superscaler. (Table I) GROUP 2 Here again 20 to 300% of the total excreted 1311 was excreted with the faeces (Table II) . Apparently, almost the same ratio of faecal 1311 to uiinary 1311 is found in subjects during administration of resin whether Na'311 or 1311-labelled protein is injected. Group 2 contained no patients with proteinlosing enteropathy whereas cases 7 and 8 in group 1 were suffering from this condition. A comparison between the two groups, omitting these two patients, showed no statistically significant difference. DISCUSSION The results indicate that about one-fourth of subcutaneously injected 1311 is excreted with the faeces during administration of resin, and excretion of roughly the same magnitude is seen in the faeces when 1311-albumin is injected intravenously. The findings suggest that wherever in the organism 158 131I-labelled albumin (or gamma globulin) is degraded to 131j about one-third of the total excretion in the faeces is found while resin is being given. Hence it seems unjustifiable that gastrointestinal breakdown of protein can be measured quantitatively by the method of Jeejeebhoy and Coghill (1961) , who found that about 60 % ofthe radioactivity ofjejunal juice originating from intravenously injected 1311-albumin may be precipitated with trichloracetic acid (about 35% is non-ionic iodine) whereas only about 5% is free iodine. In another investigation, Wetterfors, Gullberg, Liljedahl, Plantin, Birke, and Olhagen (1960) drew attention to the tremendous iodine-clearance of the stomach. Nevertheless, patients with gastrointestinal protein loss show a greater faecal excretion of 1311 than normals when investigated according to the method of Jeejeebhoy and Coghill (1961) . Their method, therefore, is useful in diagnosis of the disease but our results suggest that the method does not measure this protein loss exactly. Our results for the excretion of 1311 from 1311-labelled protein are based on urinary clearance calculations made possible after investigations (H0edt and Munck, unpublished observations) showing that after a four days' lag period after the injection of 1311-labelled albumin no difference in clearance was found between the two following six-day periods. A decrease in clearance in the 'resin investigations' must therefore be equivalent to a correspondingly raised faecal output.
RESULTS

GROUP 1 The results
SUMMARY
When anion-binding resin is administered by mouth, the excretion of 1311 in the faeces is roughly of the same magnitude whether 1311 is given parenterally as Nal31I or as 1311-labelled albumin. Methods which measure protein breakdown in the gastrointestinal tract by the use of resin and 1311-labelled albumin are therefore not valuable in determining whether faecal 1311 originates from gastrointestinal protein breakdown or from 1311-labelled albumin broken down in other sites of the body.
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